Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Harvard Business School
Medtronic

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Idalopirdine

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Idalopirdine: Sponsors, patents, clinical trial progress

Idalopirdine is an investigational drug.

There have been 7 clinical trials for Idalopirdine. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Alzheimer Disease and [disabled in preview]. The leading clinical trial sponsors are H. Lundbeck A/S and [disabled in preview].

There are twelve US patents protecting this investigational drug and one hundred and sixty-one international patents.

Recent Clinical Trials for Idalopirdine
TitleSponsorPhase
Positron Emission Tomography (PET) Study in Patients With Alzheimer's DiseaseH. Lundbeck A/SPhase 1
Bioequivalence Study of Idalopirdine in Healthy SubjectsH. Lundbeck A/SPhase 1
Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy MenH. Lundbeck A/SPhase 1

See all Idalopirdine clinical trials

Clinical Trial Summary for Idalopirdine

Top disease conditions for Idalopirdine
Top clinical trial sponsors for Idalopirdine

See all Idalopirdine clinical trials

US Patents for Idalopirdine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Idalopirdine   See Pricing Polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzyla- mine hydrochloride for the treatment of Alzheimer's disease H. LUNDBECK A/S (Valby, DK)   See Pricing
Idalopirdine   See Pricing N-(2-Arylethyl) benzylamines as antagonists of the 5-HT.sub.6 receptor Eli Lilly and Company (Indianapolis, IN)   See Pricing
Idalopirdine   See Pricing N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor Eli Lilly (Indianapolis, IN)   See Pricing
Idalopirdine   See Pricing Tryptamine sulfonamides as 5-HT.sub.6 antagonists Merck Sharp & Dohme Corp. (Rahway, NJ)   See Pricing
Idalopirdine   See Pricing Processes for the manufacture of a pharmaceutically active agent H. Lundbeck A/S (Valby, DK)   See Pricing
Idalopirdine   See Pricing Processes for the manufacture of a pharmaceutically active agent H. Lundbeck A/S (Copenhagen-Valby, DK)   See Pricing
Idalopirdine   See Pricing Application of 5-HT.sub.6 receptor antagonists for the alleviation of cognitive deficits of down syndrome The University of Utah Research Foundation (Salt Lake City, UT)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Idalopirdine

Drugname Country Document Number Estimated Expiration Related US Patent
Idalopirdine Argentina 101109 2034-07-04   See Pricing
Idalopirdine Australia 2015282909 2034-07-04   See Pricing
Idalopirdine Brazil 112017000127 2034-07-04   See Pricing
Idalopirdine Canada 2951794 2034-07-04   See Pricing
Idalopirdine Chile 2017000002 2034-07-04   See Pricing
Idalopirdine China 106458889 2034-07-04   See Pricing
Idalopirdine Costa Rica 20160605 2034-07-04   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Express Scripts
Boehringer Ingelheim
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.